CJC-1295 vs Ipamorelin
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of CJC-1295 and Ipamorelin (also searched as Ipamorelin vs CJC-1295) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
CJC-1295 centers on muscle, while Ipamorelin leans toward metabolic. On indexed research, CJC-1295 is ahead (CJC-1295: 11 studies, Human clinical; Ipamorelin: 6, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •CJC-1295 is strongest for muscle; Ipamorelin for metabolic.
- •Evidence: CJC-1295 Human clinical (11 studies) vs Ipamorelin Human evidence (6).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
GHRH analogue | GH/IGF-1 modulation
Growth Hormone Secretagogue | Selective GHRP
CJC-1295 vs Ipamorelin: side-by-side
| Metric | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | Muscle | GH |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 11 | 6 |
| Research level | Limited Research | Well Studied |
| Strongest effect | Muscle & body comp | Metabolic & appetite |
| Healing & recovery | 3.0▲ | 2.0 |
| Muscle & body comp | 4.0▲ | 3.0 |
| Metabolic & appetite | 3.0▲ | 3.0▲ |
| Neuro & mood | 2.0▲ | 2.0▲ |
| Sleep & circadian | 3.0▲ | 1.0 |
| Inflammation & immune | 2.0▲ | 1.0 |
| Skin & aesthetics | 2.0▲ | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Mechanism | GHRH (1–29) analog, modified | Selective GH secretagogue / ghrelin-receptor agonist |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~30 min | ~2 h |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is CJC-1295?
GHRH analogue used in research contexts for GH/IGF-1 modulation, muscle and bone density, sleep, and recovery.
Full CJC-1295 profile, mechanism & studies →What is Ipamorelin?
Ipamorelin is a synthetic peptide that acts as a selective agonist of the growth hormone secretagogue receptor, primarily stimulating growth hormone release. Its potential therapeutic applications are being explored in various contexts, including weight management and pain modulation.
Full Ipamorelin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | CJC-1295 | 3.0/5 effect signal |
| Muscle | CJC-1295 | 4.0/5 effect signal |
| Metabolic | Even | Both ~3.0/5 |
| Neuro | Even | Both ~2.0/5 |
| Sleep | CJC-1295 | 3.0/5 effect signal |
| Inflammation | CJC-1295 | 2.0/5 effect signal |
| Skin | Even | Both ~2.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack CJC-1295 and Ipamorelin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
CJC-1295 vs Ipamorelin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
CJC-1295 has 11 approved studies indexed (Human clinical), and Ipamorelin has 6 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is CJC-1295 or Ipamorelin better?
It depends on your goal. CJC-1295 is strongest for muscle; Ipamorelin for metabolic. CJC-1295 has more indexed studies (11). See the goal-by-goal breakdown above.
Is CJC-1295 or Ipamorelin better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is CJC-1295 or Ipamorelin better for muscle?
CJC-1295 leads on the muscle & body-composition axis (4.0/5).
Which has more research, CJC-1295 or Ipamorelin?
CJC-1295 has 11 approved studies indexed (Human clinical); Ipamorelin has 6 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack CJC-1295 and Ipamorelin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of CJC-1295 vs Ipamorelin?
CJC-1295: no community-reported effects logged yet. Ipamorelin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is CJC-1295 or Ipamorelin FDA-approved?
CJC-1295 is a research-use compound and is not FDA-approved. Ipamorelin is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Ipamorelin better than CJC-1295?
For metabolic, Ipamorelin has the edge; for muscle, CJC-1295 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
CJC-1295 and Ipamorelin are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.